Author Archives: donttradeourlivesaway

MSF cautions India on IP inclusion in RCEP talks

Source:Livemint August 26,2014 Mumbai: Medecins Sans Frontieres (MSF), or Doctors Without Borders, an international not-for-profit organisation working in the field of access to affordable medicines, has cautioned India on the inclusion of intellectual property (IP) in the ongoing negotiations of the … Continue reading

Posted in FTAs, Generic drug, HIV/Aids, Intellectual Property, IP Rights, Right to Health, WTO | Tagged , , , | Leave a comment

Can India afford to stay out of FTAs?

Source: Financial Express August 28,2014 SUMMARY FTAs are here to stay and cannot be wished away. We need to devise ways to better manage and more effectively utilise them. For quite some time India’s engagement with free trade agreements (FTAs) … Continue reading

Posted in ASEAN, FTAs, TPPA, Trans-Pacific Partnership Agreement, Transatlantic Trade and Investment Partnership (TTIP) | Tagged , , , , , , , | Leave a comment

Médecins Sans Frontières Warns About IP Inclusion In Asian FTA

August 27,2014 The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to … Continue reading

Posted in ASEAN, FTAs, Generic drug, IP Rights, patent, Right to Health, TRIPS plus | Tagged , , , , , , | Leave a comment

MSF responds to European approval of hepatitis C drug daclatasvir

On 27 August 2014, the European Commission (EC) and the European MedicinesAgency (EMA) became the second stringent regulatory authority (after Japanin July) to approve new direct-acting antiviral (DAA) daclatasvir, used totreat hepatitis C. Daclatasvir is the third DAA – a … Continue reading

Posted in Hepatitis - C, Price Negotiations, Right to Health | Tagged , , , , , , | Leave a comment

TIME TO ACT: ENSURE ACCESS TO AFFORDABLE BIOTHERAPEUTIC PRODUCTS

CIVIL SOCIETY STATEMENT FOR PRE-ICDRA AND ICDRA We, the undersigned organizations, bring to the attention of Drug Regulatory Authorities, WHO, Member States and other participants of Pre and International Conference on Drug Regulatory Authorities (Pre-ICDRA and ICDRA) and community in general the following … Continue reading

Posted in Biologics, biosimilars, Intellectual Property, International Non-Proprietary Names | Leave a comment

MSF Letter to Indian government – IP negotiations in the Regional Comprehensive Economic Partnership

Source: MSF Access Campaign 25 August 2014 Ahead of the RCEP Ministerial Conference to be held in Myanmar on 27-28 August 2014, see letter from Medecins Sans Frontieres addressed to the Indian Minister of State for Commerce & Industry regarding … Continue reading

Posted in Regional Comprehensive Economic Partnership, TRIPS flexibilities, TRIPS plus | Leave a comment

Govt set to revise patent norms for pharma

Source: Business Standard 19 August 2014, Sushmi Dey The government is set to revise the guidelines for evaluating applications seeking intellectual property rights (IPR) for pharmaceuticals. This follows an increasing number of drug patent filings, along with litigation between innovator … Continue reading

Posted in Indian Patent Law, Intellectual Property, Sec 3 (d), TRIPS flexibilities | Leave a comment